Versatile polymer microspheres for injection therapy: aspects of fluoroscopic traceability and biofunctionalization

Autohors: Saralidze K, Knetsch ML, van der Marel C, Koole LH.

Keywords: Fibroblasts, Cytology, Microspheres, Polymers, Therapeutic Use, Injections


Synthesis and characterization of a series of novel microspheres featuring (i) radiopacity (i.e., clear fluoroscopic traceability) and (ii) an outer surface exposing aldehyde groups are reported. The aldehydes allowed us to tether proteins onto the particles’ surface under mild conditions, under which the protein conformation and, hence, structural motifs for biorecognition are preserved. Essential monomer building blocks were (i) 4-iodobenzoyl-2-oxo-ethylmethacrylate (4-IEMA) for radiopacity and (ii) propenal for surface tethering of proteins. The particles demonstrated good X-ray visibility and cytocompatibility. Procedures to couple proteins onto the surface were optimized using fluorescent bovine serum albumin (FITC-BSA) or collagen (FITC-collagen). Furthermore, radiopaque microparticles with unlabeled bovine collagen type I were produced. The presence of immobilized collagen was verified with narrow-scan X-ray photoelectron spectroscopy. Fibroblasts readily adhere to and grow on the collagen-modified surfaces, whereas this was much less the case for the unmodified controls. The results led us to suggest that immobilized nondenatured collagen may transform filler particles from passive space-occupying objects to particles that cross-talk with surrounding tissues.

Biomacromolecules. 2010 Dec 13;11(12):3556-62. doi: 10.1021/bm1010273. Epub 2010 Oct 20.

  • Latest news:

    February 2015:

    PMLF laboratory technology/biotechnology accreditation


    February 2014:

    INterface BIOmaterials BV participates in the LSH impuls project: “KidneyPort


    August 2013:

    PMLF laboratory technology accreditation


    July 2013:

    PMLF process engineering accreditation


    February 2013:

    CE certification on X-Spheres™


    November 2012:

    ISO 13485 certification


    January 2011:

    INterface BIOmaterials BV participates in the Interreg IVa project: “BioMiMedics”


    January 2010:

    INterface BIOmaterials BV participates in the “iNephron” project subsidized by the Dutch Kidney Foundation